Peptide therapeutics for metabolic disorders

Peptide therapeutics for metabolic disorders

Peptide therapeutics for metabolic disorders (#61)

Ved Srivastava ¹

Intarcia Therapeutics, CARY, NC, United States

Type 2 Diabetes and obesity are the key threats to global health, and it is a pandemic. The gut hormones such as GLP-1 and Glucagon, regulate energy homeostasis and metabolism. The analogs having action on both GLP-1 and Glucagon receptors have shown promise for the treatment of T2D and obesity. This presentation will discuss a highly selective Glucagon agonist (ICA 1560349) in combination with Exenatide, a GLP-1 selective agonist demonstrates a significant reduction of body weight and Glucose in rodents, and have the potential for the treatment of obesity and T2DM.

Authors contributing to this presentation.

Srivastava, V

Dr. Ved Srivastava is Vice President of Peptide Chemistry at Intarcia Therapeutics. Prior to that, he was the Head of Peptide Chemistry at GlaxoSmithKline, USA; and in the leadership role with Amylin Pharmaceuticals, USA. Vedis a Bioentrepreneur and he is President-Elect of the American Peptide Society. Ved has significantly participated in the development and commercialization of SymlinTM, ByettaTM, and BydeureonTM, first-in-class medicines for the treatment of diabetes. He is the Editor of three books: Peptide-based Drug Discovery, Comprehensive Medicinal Chemistry III - Biologics Medicine (Vol 6) and ‘Peptide 2015’. He earned a Ph.D. in organic chemistry from the University of Lucknow, India.

Peptide therapeutics for metabolic disorders (#61)

Add notes

Srivastava, V

Login